Stella Pharma Co., Ltd.
Basic information
- Head office
- 3-2-7 Karasuma, Chuo-ku, Osaka, Osaka Prefecture, ORIX Karasuma Building
- Chief executive
- Kouji Uehara
- Capital
- 3,000,000,000 (30 100 million)
- Employees (non-consolidated)
- 44 people
- Employees (consolidated)
- 47 people
- Start date
- 2007-06-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
| 株式会社産業革新機構(現株式会社INCJ) | ||||||||
| 海南博鰲(ボアオ)楽城国際医療旅遊先行区 | ||||||||
| 独立行政法人科学技術振興機構(略称 JST) | ||||||||
| 住友 |
Network
History
Initiated Phase I clinical trial of SPM-011 for brain tumors in Japan (target patients: recurrent malignant glioma).![]()
Relocated the research laboratory to the Osaka Prefecture University BNCT Research Center to improve R&D efficiency (Sakai City, Naka-ku).![]()
Initiated Phase I clinical trial of SPM-011 for head and neck cancer in Japan (target patients: unresectable locally recurrent head and neck cancer and unresectable locally advanced head and neck cancer (non-squamous cell carcinoma)).![]()
Initiated Phase II clinical trial of SPM-011 for brain tumors in Japan (target patients: recurrent malignant glioma).![]()
Implemented capital increase through a third-party allotment with the Industrial Innovation Organization Inc. (now INCJ) and Sumitomo Heavy Industries as underwriters (Stella Chemifa's voting share decreased to 64%).![]()
Implemented capital increase through a third-party allotment with the Industrial Innovation Organization Inc. (now INCJ) and Sumitomo Heavy Industries as underwriters.![]()
Initiated Phase II clinical trial of SPM-011 for head and neck cancer in Japan (target patients: unresectable locally recurrent head and neck cancer and unresectable locally advanced head and neck cancer (non-squamous cell carcinoma)).![]()
SPM-011 designated as a subject item (drug) under the Ministry of Health, Labour and Welfare's pioneering review designation system.![]()
Obtained manufacturing and sales approval for BNCT drug Stereobulin® (SPM-011) with indication for 'unresectable locally advanced or locally recurrent head and neck cancer'.![]()
News
There is no news.
Public records
National Tax Agency basic information5120001124194
- Trade name
- ステラファーマ株式会社
- Trade name (kana)
- ステラファーマ
- Name in English
- Corporation type
- 301
- Address
- 〒541-0043 大阪府大阪市中央区高麗橋3丁目2番7号ORIX高麗橋ビル
- Postal code
- 5410043
- Prefecture code
- 27
- City code
- 128
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-07-20
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 4204231
METI gBizINFO5120001124194
- Corporate number
- 5120001124194
- Trade name
- ステラファーマ株式会社
- Trade name (kana)
- ステラファーマ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 大阪府大阪市中央区高麗橋3丁目2番7号ORIX高麗橋ビル
- Postal code
- 5410043
- Prefecture
- 大阪府
- Prefecture code
- 27
- City or district
- 大阪市中央区
- City code
- 128
- Street address
- 高麗橋3丁目2番7号ORIX高麗橋ビル
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 上原 幸樹
- Capital
- 2859218000
- Employees
- 47
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-07-20
- Key information
- 5120001124194